Twist Bioscience partners with Lilly TuneLab to advance antibody discovery
The agreement provides Twist-generated characterization data to train AI models, accelerating drug candidate selection.
See the latest news and media coverage for Twist Bioscience. We track all announcements, press releases, and industry mentions in real time, all in one place.
Synthetic biology tools and services company
twistbioscience.comLast updated
In short: Twist Bioscience announced key AI partnerships with Lilly TuneLab and Anthropic while pricing an upsized $300 million stock offering.
The agreement provides Twist-generated characterization data to train AI models, accelerating drug candidate selection.
The company plans to fund R&D and manufacturing expansion with proceeds from this underwritten public offering of common stock.
These equity awards comply with Nasdaq Listing Rule 5635(c)(4) and vest over a 48-month period for 24 recently hired individuals.
The biotech company released Q3 FY2026 earnings for the period ended June 30, including a live webcast replay and detailed investor presentation.
Twist Bioscience CEO Emily Leproust said at Baird's 2026 Global Healthcare Conference that the company expects fiscal Q4 2026 revenue of ...
Twist Bioscience Corporation TWST on Wednesday announced an agreement with Lilly TuneLab, a collaborative AI/ML drug ...
Twist Bioscience shares were up 17% in afternoon trading on Wednesday after the company said it was selected by Anthropic as an independent evaluator for...
Twist Bioscience Corporation (Nasdaq: TWST) ("Twist"), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten public offering of 3,125,000...
Track Twist Bioscience and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Twist Bioscience and other trending companies.